Aldeyra Therapeutics
ALDX
89 hedge funds and large institutions have $197M invested in Aldeyra Therapeutics in 2022 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 22 increasing their positions, 32 reducing their positions, and 20 closing their positions.
34% more capital invested
Capital invested by funds: $147M → $197M (+$50.5M)
0.01% more ownership
Funds ownership: 63.38% → 63.39% (+0.01%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less funds holding
Funds holding: 95 → 89 (-6)
30% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 20
31% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 32
37% less call options, than puts
Call options by funds: $1.6M | Put options by funds: $2.55M
Top Buyers
| 1 |
PA
Perceptive Advisors
New York
|
+$8.68M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$4.2M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.58M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
+$3.01M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.26M |
Top Sellers
| 1 |
Goldman Sachs
New York
|
-$5.98M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
-$4.65M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4.41M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$3.92M |
| 5 |
Millennium Management
New York
|
-$3.54M |
ALDX Hedge Fund Activity: Q3 2022 in Review
89 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q3 2022, worth a combined $197M — up 34% from $147M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of ALDX and 14 opened new positions — a net loss of 6 holders — while 32 trimmed existing stakes and 22 added.
The largest buyer was Perceptive Advisors, adding an estimated $8.68M. The largest seller was Goldman Sachs, cutting an estimated $5.98M.
- 89 institutional investors held Aldeyra Therapeutics (ALDX) as of Q3 2022, down from 95 in Q2 2022.
- Funds reported $197M of Aldeyra Therapeutics stock for Q3 2022, up 34% quarter-over-quarter.
- 14 funds opened new Aldeyra Therapeutics positions in Q3 2022 and 20 closed out, a net change of -6 holders.
- The largest Aldeyra Therapeutics buyer in Q3 2022 was Perceptive Advisors, an estimated $8.68M added.
- The largest Aldeyra Therapeutics seller in Q3 2022 was Goldman Sachs, an estimated $5.98M sold.
Based on aggregated 13F filings for Q3 2022.